Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jul;35(7):1334–1337. doi: 10.1128/aac.35.7.1334

Synergy between cilofungin and amphotericin B in a murine model of candidiasis.

L H Hanson 1, A M Perlman 1, K V Clemons 1, D A Stevens 1
PMCID: PMC245167  PMID: 1929290

Abstract

The efficacies of cilofungin and amphotericin B separately and together in mice with disseminated candidiasis were studied. Male CD-1 mice (age, 5 weeks) were infected intravenously with 3 X 10(5) CFU of Candida albicans. At 4 days postinfection, intraperitoneal therapy was initiated and was continued for 14 days. Therapy groups included those given cilofungin at 6.25 or 62.5 mg/kg/day (given twice daily), amphotericin B at 0.625 mg/kg/day (given once daily), cilofungin at 6.25 mg/kg/day plus amphotericin B, and cilofungin at 62.5 mg/kg/day plus amphotericin B. Mice were observed through 30 days postinfection. All infected untreated mice died of infection between days 6 and 18. Eighty-five percent of mice receiving cilofungin at 6.25 mg/kg/day died between days 13 and 30. All other mice survived. Quantitative determination of the number of CFU of C. albicans in the spleens and kidneys of all survivors revealed that mice that had received both drugs had lower residual burdens of C. albicans. All mice treated with cilofungin at 62.5 mg/kg/day plus amphotericin B had sterile spleens, whereas 42 to 58% of mice given cilofungin or amphotericin B monotherapy had sterile spleens. All kidneys were infected in mice which had received cilofungin at 62.5 mg/kg/day or amphotericin B. Neither organ was infected in 17% of each group receiving combination therapy with cilofungin and amphotericin B. The number of CFU in the kidneys of mice treated with cilofungin at 62.5 mg/kg/day plus amphotericin B was lower than those cultured from mice treated with cilofungin at 62.5 mg/kg/day (P less than 0.001, Mann-Whitney) or amhotericin B (P less than 0.05). Modest synergy was noted in inhibition of the C. albicans isolate in vitro. Pharmacokinetic studies showed elevated levels of cilofungin but not amphotericin B in sera of mice treated with combined therapy compared with those in mice given monotherapy. No overt toxicity was evident with any regimen. The mechanism of increased efficacy may be altered cilofungin distribution, excretion, or metabolism; antifungal synergy; or both. These results indicate that concurrent cilofungin-amphotericin B therapy has synergistic or additive efficacy in vivo.

Full text

PDF
1334

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benson J. M., Nahata M. C. Clinical use of systemic antifungal agents. Clin Pharm. 1988 Jun;7(6):424–438. [PubMed] [Google Scholar]
  2. Bulo A. N., Bradley S. F., Kauffman C. A. The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species. Mycoses. 1989 Mar;32(3):151–157. doi: 10.1111/j.1439-0507.1989.tb02224.x. [DOI] [PubMed] [Google Scholar]
  3. Galgiani J. N., Sun S. H., Clemons K. V., Stevens D. A. Activity of cilofungin against Coccidioides immitis: differential in vitro effects on mycelia and spherules correlated with in vivo studies. J Infect Dis. 1990 Oct;162(4):944–948. doi: 10.1093/infdis/162.4.944. [DOI] [PubMed] [Google Scholar]
  4. Gordee R. S., Zeckner D. J., Ellis L. F., Thakkar A. L., Howard L. C. In vitro and in vivo anti-Candida activity and toxicology of LY121019. J Antibiot (Tokyo) 1984 Sep;37(9):1054–1065. doi: 10.7164/antibiotics.37.1054. [DOI] [PubMed] [Google Scholar]
  5. Hanson L. H., Stevens D. A. Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens. Antimicrob Agents Chemother. 1989 Aug;33(8):1391–1392. doi: 10.1128/aac.33.8.1391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hobbs M., Perfect J., Durack D. Evaluation of in vitro antifungal activity of LY121019. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):77–80. doi: 10.1007/BF01962182. [DOI] [PubMed] [Google Scholar]
  7. Lefler E., Stevens D. A. Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother. 1984 Apr;25(4):450–454. doi: 10.1128/aac.25.4.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lefler E., Stevens D. A. New azole compounds: vibunazole (Bay n7133) and Bay L9139, compared with ketoconazole in the therapy of systemic candidosis and in pharmacokinetic studies, in mice. J Antimicrob Chemother. 1985 Jan;15(1):69–75. doi: 10.1093/jac/15.1.69. [DOI] [PubMed] [Google Scholar]
  9. Morrison C. J., Stevens D. A. Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis. Antimicrob Agents Chemother. 1990 May;34(5):746–750. doi: 10.1128/aac.34.5.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Spitzer E. D., Travis S. J., Kobayashi G. S. Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):80–81. doi: 10.1007/BF01962183. [DOI] [PubMed] [Google Scholar]
  11. Stevens D. A., Vo P. T. Synergistic interaction of trimethoprim and sulfamethoxazole on Paracoccidioides brasiliensis. Antimicrob Agents Chemother. 1982 May;21(5):852–854. doi: 10.1128/aac.21.5.852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Stiller R. L., Bennett J. E., Scholer H. J., Wall M., Polak A., Stevens D. A. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis. 1983 Jun;147(6):1070–1077. doi: 10.1093/infdis/147.6.1070. [DOI] [PubMed] [Google Scholar]
  13. Tucker R. M., Williams P. L., Arathoon E. G., Stevens D. A. Treatment of mycoses with itraconazole. Ann N Y Acad Sci. 1988;544:451–470. doi: 10.1111/j.1749-6632.1988.tb40443.x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES